<p>輝瑞（NYSE:PFE - 獲取免費報告）在摩根大通發佈的一份報告中將其目標價格從 30.00 美元下調至 28.00 美元，報告於週三發佈，Benzinga 報道。該券商目前對這家生物製藥公司的股票給予 “中性” 評級。摩根大通的目標價格表明該股票相較於前一交易日收盤價有 15.34% 的上漲潛力。</p>
<ul>
<li>專利懸崖掠奪者：GSK 以 106 億美元收購 Nuvalent</li>
</ul>
<p>輝瑞的股票在其他幾份報告中也成為話題。美國銀行在 4 月 9 日的報告中將輝瑞的目標價格從 27.00 美元下調至 26.00 美元，並對該股票給予 “中性” 評級。華爾街 Zen 在週六的研究報告中將輝瑞的評級從 “買入” 下調至 “持有”。瑞銀集團在 5 月 27 日的研究報告中重申了 “中性” 評級，並將輝瑞的目標價格設定為 27.00 美元。摩根士丹利在 4 月 10 日的報告中將輝瑞的目標價格從 27.00 美元上調至 28.00 美元，並給予該股票 “等權重” 評級。最後，Cantor Fitzgerald 在週一的研究報告中重新發布了 “中性” 評級，並將輝瑞的目標價格設定為 27.00 美元。一位研究分析師對該股票給予了強烈買入評級，四位給予了買入評級，十四位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “持有”，平均目標價格為 28.56 美元。</p>
<p><strong>獲取我們最新的輝瑞股票報告</strong></p>
<h2>輝瑞股票上漲 0.9%</h2>
<ul>
<li>2 種應對大型製藥專利懸崖的方式</li>
</ul>
<p>輝瑞股票在週三上漲 0.21 美元，達到 24.28 美元。該公司的交易量為 9,945,070 股，而其平均交易量為 42,591,492 股。輝瑞的 1 年低點為 23.11 美元，1 年高點為 28.75 美元。該公司的債務與股本比率為 0.67，速動比率為 0.94，流動比率為 1.25。該股票的 50 日移動平均線為 25.51 美元，200 日移動平均線為 26.21 美元。該股票的市值為 1383.6 億美元，市盈率為 18.50，貝塔值為 0.35。</p>
<p>輝瑞（NYSE:PFE - 獲取免費報告）最後一次公佈季度財報是在 5 月 5 日，生物製藥公司報告每股收益（EPS）為 0.75 美元，超出市場共識預期的 0.72 美元，超出幅度為 0.03 美元。輝瑞的股本回報率為 19.44%，淨利潤率為 11.83%。該季度的營業收入為 144.5 億美元，而市場共識預期為 138.4 億美元。在去年同期，該公司每股收益為 0.92 美元。輝瑞的收入較去年同期增長了 5.4%。輝瑞已將其 2026 財年的指導目標設定為每股收益 2.800-3.000 美元。作為一個整體，賣方分析師預測輝瑞在當前年度的每股收益將達到 2.98 美元。</p>
<h2>機構投資者對輝瑞的看法</h2>
<ul>
<li>5 只高收益股票以保護您的投資組合免受風暴影響</li>
</ul>
<p>機構投資者最近增加或減少了對該公司的持股。先鋒集團在第四季度將其在輝瑞的持股增加了 1.3%。先鋒集團目前擁有輝瑞生物製藥公司 541,346,182 股股票，價值 13,479,520,000 美元，在上個季度又購買了 7,031,162 股。道富銀行在第四季度將其在輝瑞的持股增加了 0.5%。道富銀行目前擁有輝瑞生物製藥公司 300,445,164 股股票，價值 7,481,085,000 美元，在此期間又購買了 1,357,756 股。Geode Capital Management LLC 在第四季度將其在輝瑞的持股增加了 0.9%。Geode Capital Management LLC 目前擁有輝瑞生物製藥公司 130,192,081 股股票，價值 3,235,642,000 美元，在上個季度又購買了 1,184,728 股。摩根士丹利在第四季度將其在輝瑞的持股增加了 19.2%。摩根士丹利目前擁有輝瑞生物製藥公司 89,113,604 股股票，價值 2,218,929,000 美元，在此期間又收購了 14,342,946 股。最後，挪威銀行在第四季度購買了輝瑞的新頭寸，價值約為 1,830,986,000 美元。68.36% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於輝瑞的熱門頭條</h2>
<p>以下是本週影響輝瑞的主要新聞：</p>
<ul>
<li>積極情緒：輝瑞獲得 FDA 批准在 HER2 陽性乳腺癌中使用 IBRANCE，為公司提供了一個新的臨牀和商業里程碑，可能支持未來的銷售。輝瑞（PFE）在 HER2 陽性乳腺癌中獲得 FDA 批准使用 IBRANCE</li>
<li>積極情緒：多篇文章將輝瑞稱為 “極其便宜” 的醫療保健股票，暗示價值投資者注意到其低估值和現金生成能力。7 月值得購買的 2 只極其便宜的醫療保健股票</li>
<li>積極情緒：輝瑞異常高的股息收益率吸引了收入投資者的關注，這有助於支持對該股票的需求。2 只因其股息而值得購買的醫療保健股票——以及輝瑞為何不在其中</li>
</ul>
<h2>輝瑞公司簡介</h2>
<p>（獲取免費報告）</p>
<p>輝瑞公司（NYSE: PFE）是一家總部位於紐約市的跨國生物製藥公司。公司成立於 1849 年，由查爾斯·輝瑞和查爾斯·厄哈特創立，專注於研究、開發、生產和商業化廣泛的藥物和疫苗，以改善人類健康。其業務涵蓋發現研究、臨牀開發、監管事務、生產和全球商業分銷，涉及多個治療領域。</p>
<p>輝瑞的產品組合和研發管道涵蓋腫瘤學、免疫學、心臟病學、內分泌學、罕見疾病、醫院急救和抗感染藥物，以及一個可觀的疫苗業務。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而非輝瑞</li>
<li>想在 IPO 之前接觸 Anthropic？這兩家 AI 巨頭已經在其中</li>
<li>3 只被打壓的交易，可能在市場修正中獲利</li>
<li>7 月值得購買的 5 只股息王，具有不可抗拒的價值和收益</li>
<li>這 3 只現金流股票為投資者提供的不僅僅是增長潛力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
<p>在考慮輝瑞之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而輝瑞並不在名單上。</p>
<p>雖然輝瑞目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

輝瑞

瑞銀集團

道富銀行

摩根大通

JPMO

<p>摩根大通將輝瑞（PFE）的目標股價從 30.00 美元下調至 28.00 美元，維持 “中性” 評級。這一調整與其他分析師的類似調整相呼應，包括美國銀行和瑞銀集團，反映出一致的 “持有” 評級，平均目標價為 28.56 美元。同時，輝瑞報告了強勁的季度收益，超出每股收益和收入的預期，並且像先鋒集團和道富銀行這樣的機構投資者增加了他們的持股</p>

<p>Pfizer (NYSE:PFE - Get Free Report) had its price objective decreased by analysts at JPMorgan Chase &amp; Co. from $30.00 to $28.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a &#34;neutral&#34; rating on the biopharmaceutical company's stock. JPMorgan Chase &amp; Co.'s price objective indicates a potential upside of 15.34% from the stock's previous close.</p>
<div class="lb-trans"><p>輝瑞（NYSE:PFE - 獲取免費報告）在摩根大通發佈的一份報告中將其目標價格從 30.00 美元下調至 28.00 美元，報告於週三發佈，Benzinga 報道。該券商目前對這家生物製藥公司的股票給予 “中性” 評級。摩根大通的目標價格表明該股票相較於前一交易日收盤價有 15.34% 的上漲潛力。</p>
</div><ul>
<li>Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion</li>
</ul>
<div class="lb-trans"><ul>
<li>專利懸崖掠奪者：GSK 以 106 億美元收購 Nuvalent</li>
</ul>
</div><p>PFE has been the topic of several other reports. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, April 9th. Wall Street Zen downgraded Pfizer from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. UBS Group reaffirmed a &#34;neutral&#34; rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. Morgan Stanley lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, April 10th. Finally, Cantor Fitzgerald reissued a &#34;neutral&#34; rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average price target of $28.56.</p>
<div class="lb-trans"><p>輝瑞的股票在其他幾份報告中也成為話題。美國銀行在 4 月 9 日的報告中將輝瑞的目標價格從 27.00 美元下調至 26.00 美元，並對該股票給予 “中性” 評級。華爾街 Zen 在週六的研究報告中將輝瑞的評級從 “買入” 下調至 “持有”。瑞銀集團在 5 月 27 日的研究報告中重申了 “中性” 評級，並將輝瑞的目標價格設定為 27.00 美元。摩根士丹利在 4 月 10 日的報告中將輝瑞的目標價格從 27.00 美元上調至 28.00 美元，並給予該股票 “等權重” 評級。最後，Cantor Fitzgerald 在週一的研究報告中重新發布了 “中性” 評級，並將輝瑞的目標價格設定為 27.00 美元。一位研究分析師對該股票給予了強烈買入評級，四位給予了買入評級，十四位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “持有”，平均目標價格為 28.56 美元。</p>
</div><p><strong>Get Our Latest Stock Report on PFE</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的輝瑞股票報告</strong></p>
</div><h2>Pfizer Stock Up 0.9%</h2>
<div class="lb-trans"><h2>輝瑞股票上漲 0.9%</h2>
</div><ul>
<li>2 Ways to Play the Big Pharma Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>2 種應對大型製藥專利懸崖的方式</li>
</ul>
</div><p>Shares of Pfizer stock traded up $0.21 on Wednesday, hitting $24.28. The company had a trading volume of 9,945,070 shares, compared to its average volume of 42,591,492. Pfizer has a 1 year low of $23.11 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a 50 day moving average of $25.51 and a 200-day moving average of $26.21. The stock has a market capitalization of $138.36 billion, a price-to-earnings ratio of 18.50 and a beta of 0.35.</p>
<div class="lb-trans"><p>輝瑞股票在週三上漲 0.21 美元，達到 24.28 美元。該公司的交易量為 9,945,070 股，而其平均交易量為 42,591,492 股。輝瑞的 1 年低點為 23.11 美元，1 年高點為 28.75 美元。該公司的債務與股本比率為 0.67，速動比率為 0.94，流動比率為 1.25。該股票的 50 日移動平均線為 25.51 美元，200 日移動平均線為 26.21 美元。該股票的市值為 1383.6 億美元，市盈率為 18.50，貝塔值為 0.35。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the company posted $0.92 earnings per share. Pfizer's revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer will post 2.98 earnings per share for the current year.</p>
<div class="lb-trans"><p>輝瑞（NYSE:PFE - 獲取免費報告）最後一次公佈季度財報是在 5 月 5 日，生物製藥公司報告每股收益（EPS）為 0.75 美元，超出市場共識預期的 0.72 美元，超出幅度為 0.03 美元。輝瑞的股本回報率為 19.44%，淨利潤率為 11.83%。該季度的營業收入為 144.5 億美元，而市場共識預期為 138.4 億美元。在去年同期，該公司每股收益為 0.92 美元。輝瑞的收入較去年同期增長了 5.4%。輝瑞已將其 2026 財年的指導目標設定為每股收益 2.800-3.000 美元。作為一個整體，賣方分析師預測輝瑞在當前年度的每股收益將達到 2.98 美元。</p>
</div><h2>Institutional Investors Weigh In On Pfizer</h2>
<div class="lb-trans"><h2>機構投資者對輝瑞的看法</h2>
</div><ul>
<li>5 High-Yield Stocks to Shield Your Portfolio From the Storm</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只高收益股票以保護您的投資組合免受風暴影響</li>
</ul>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after buying an additional 7,031,162 shares in the last quarter. State Street Corp increased its position in shares of Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company's stock valued at $7,481,085,000 after buying an additional 1,357,756 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock worth $3,235,642,000 after buying an additional 1,184,728 shares in the last quarter. Morgan Stanley boosted its position in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after acquiring an additional 14,342,946 shares during the period. Finally, Norges Bank purchased a new position in Pfizer during the fourth quarter valued at approximately $1,830,986,000. 68.36% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對該公司的持股。先鋒集團在第四季度將其在輝瑞的持股增加了 1.3%。先鋒集團目前擁有輝瑞生物製藥公司 541,346,182 股股票，價值 13,479,520,000 美元，在上個季度又購買了 7,031,162 股。道富銀行在第四季度將其在輝瑞的持股增加了 0.5%。道富銀行目前擁有輝瑞生物製藥公司 300,445,164 股股票，價值 7,481,085,000 美元，在此期間又購買了 1,357,756 股。Geode Capital Management LLC 在第四季度將其在輝瑞的持股增加了 0.9%。Geode Capital Management LLC 目前擁有輝瑞生物製藥公司 130,192,081 股股票，價值 3,235,642,000 美元，在上個季度又購買了 1,184,728 股。摩根士丹利在第四季度將其在輝瑞的持股增加了 19.2%。摩根士丹利目前擁有輝瑞生物製藥公司 89,113,604 股股票，價值 2,218,929,000 美元，在此期間又收購了 14,342,946 股。最後，挪威銀行在第四季度購買了輝瑞的新頭寸，價值約為 1,830,986,000 美元。68.36% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Trending Headlines about Pfizer</h2>
<div class="lb-trans"><h2>關於輝瑞的熱門頭條</h2>
</div><p>Here are the key news stories impacting Pfizer this week:</p>
<div class="lb-trans"><p>以下是本週影響輝瑞的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Pfizer won FDA approval for IBRANCE in HER2-positive breast cancer, giving the company a new clinical and commercial milestone that could support future sales. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer</li>
<li>Positive Sentiment: Multiple articles highlighted Pfizer as a “dirt cheap” healthcare stock, suggesting value investors are noticing its low valuation and cash-generating profile. 2 Dirt Cheap Healthcare Stocks to Buy in July</li>
<li>Positive Sentiment: Pfizer’s unusually high dividend yield is drawing attention from income investors, which can help support demand for the shares. 2 Healthcare Stocks to Buy for Their Dividends—and Why Pfizer Isn’t One of Them</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：輝瑞獲得 FDA 批准在 HER2 陽性乳腺癌中使用 IBRANCE，為公司提供了一個新的臨牀和商業里程碑，可能支持未來的銷售。輝瑞（PFE）在 HER2 陽性乳腺癌中獲得 FDA 批准使用 IBRANCE</li>
<li>積極情緒：多篇文章將輝瑞稱為 “極其便宜” 的醫療保健股票，暗示價值投資者注意到其低估值和現金生成能力。7 月值得購買的 2 只極其便宜的醫療保健股票</li>
<li>積極情緒：輝瑞異常高的股息收益率吸引了收入投資者的關注，這有助於支持對該股票的需求。2 只因其股息而值得購買的醫療保健股票——以及輝瑞為何不在其中</li>
</ul>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>輝瑞公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>輝瑞公司（NYSE: PFE）是一家總部位於紐約市的跨國生物製藥公司。公司成立於 1849 年，由查爾斯·輝瑞和查爾斯·厄哈特創立，專注於研究、開發、生產和商業化廣泛的藥物和疫苗，以改善人類健康。其業務涵蓋發現研究、臨牀開發、監管事務、生產和全球商業分銷，涉及多個治療領域。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>輝瑞的產品組合和研發管道涵蓋腫瘤學、免疫學、心臟病學、內分泌學、罕見疾病、醫院急救和抗感染藥物，以及一個可觀的疫苗業務。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Want Anthropic Exposure Before the IPO? These 2 AI Giants Are Already There</li>
<li>3 Beaten-Down Trades That Could Pay Off in a Market Correction</li>
<li>5 Dividend Kings to Buy in July with Irristable Value and Yield</li>
<li>These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非輝瑞</li>
<li>想在 IPO 之前接觸 Anthropic？這兩家 AI 巨頭已經在其中</li>
<li>3 只被打壓的交易，可能在市場修正中獲利</li>
<li>7 月值得購買的 5 只股息王，具有不可抗拒的價值和收益</li>
<li>這 3 只現金流股票為投資者提供的不僅僅是增長潛力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮輝瑞之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，而輝瑞並不在名單上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然輝瑞目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

JPMorgan Chase & Co. Has Lowered Expectations for Pfizer (NYSE:PFE) Stock Price

- JPMorgan 將輝瑞目標價下調至 $28.00，維持 “中性” 評級。  
- 輝瑞季度營收達到 $14.45 億美元，超過市場預期。  
- 輝瑞獲得 FDA 批准，有望提升未來銷售。

Market Beat

YieldMax JPM Option Income Strategy ETF

Defiance Daily Target 2X Long JPM ETF

美國銀行

摩根士丹利

Nuvalent

葛蘭素史克

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

GSK plc Sponsored ADR

State Street® US Equity Premium Inc ETF

摩根大通已下調對輝瑞（NYSE:PFE）股票價格的預期